The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
AIDSPublished 1 June 1999
Richard Haubrich, Susan J. Little, Judith S. Currier, Donald N. Forthal, Carol A. Kemper, Gildon N. Beall
Citations548
SJR quartileQ1
SJR score1.21
SNIP0.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Self-reported poor adherence and drug or alcohol use predicted non-response of HIV RNA at 6 months of antiretroviral therapy.
Abstract
Self-reported poor adherence (< 80%) and drug or alcohol use predicted non-response of HIV RNA at 6 months of antiretroviral therapy.
Keywords
Immunology and MicrobiologyMedicine
New England Journal of MedicineA Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
2,666 Citations1997Scott M. Hammer, Kathleen Squires +14 more
Treatment with indinavir, zidovudine, and lamivudine as compared with zidvudine and lam ivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidavudine.
New England Journal of MedicineA Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
1,088 Citations1996Scott M. Hammer, David Katzenstein +10 more
Antiretroviral therapy can improve survival in patients with 200 to 500 CD4 cells per cubic millimeter and is superior to treatment with zidovudine alone, although the benefits were limited to those without previous treatment.
NatureIn vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
979 Citations1995Jon H. Condra, William A. Schleif +14 more
Five resistant variants isolated from patients undergoing therapy with the protease inhibitor MK-639 exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors, suggesting that com-bination therapy with multiple protease inhibition may not prevent loss of antiviral activity resulting from resistance selection.
JAMAImproved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy
867 Citations1998Robert S. Hogg
The HIV-infected individuals who receivedInitial therapy with regimens including stavudine or lamivudine had significantly lower mortality and longer AIDS-free survival than those who received initial therapy withregimens limited to zidovudine, didanosine, and zalcitabine.
New England Journal of MedicineHIV-Protease Inhibitors
861 Citations1998Charles Flexner
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.
New England Journal of MedicineA Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease
573 Citations1995Sven A. Danner, Andrew Carr +16 more
In this short-term study, ritonavir was well tolerated and had potent activity against HIV-1, but its clinical benefits remain to be established.
The LancetDelta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
515 Citations1996JH Darbyshire
Initiation of treatment with combinations of AZT plus ddI or ddC prolongs life and delays disease progression compared with AZT alone, and the addition of ddI to participants already treated withAZT improves survival, although the benefit appears less.
AIDS CareDeterminants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
506 Citations1996N. Singh, Cheryl Squier +4 more
The prevalence and variables associated with compliance with antiretroviral therapy in patients with human immunodeficiency virus infection, by means of a longitudinal observational study of 46 patients aged 23 to 68 years, are assessed.
New England Journal of MedicineA Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
491 Citations1995Martin Markowitz, Michael S. Saag +9 more
The protease inhibitor ritonavir is well tolerated and has a potent antiviral effect, as shown by substantial decreases in plasma viremia and significant elevations in CD4 cell counts.
The American Journal of MedicineNonadherence in Tuberculosis Treatment: Predictors and Consequences in New York City
251 Citations1997Ariel Pablos-Méndez, Charles Knirsch +3 more
The American Journal of MedicineCompliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: A cross-sectional study in a municipal hospital clinic
225 Citations1992Jeffrey H. Samet, Howard Libman +8 more
High compliance with zidovudine was achieved by HIV-infected patients in a municipal hospital clinic, many of whom had a history of intravenous drug use and may be enhanced by a patient's belief that it prolongs life and the use of a medication timer for proper dosing.
JAMAPatient Compliance and Drug Failure in Protease Inhibitor Monotherapy
193 Citations1996Geertrui F. Vanhove
Antimicrobial Agents and ChemotherapyCross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
181 Citations1995Margaret Tisdale, Richard Myers +4 more
HIV passage studies in the combined presence of two protease inhibitors demonstrated that in vitro it was possible to delay significantly selection of mutations producing resistance to one or both inhibitors.
Archives of Internal MedicineA Cohort Study of Drug Users' Compliance With Zidovudine Treatment
142 Citations1994Barbara Broers
Injecting drug users tend to delay the start of zidovudine treatment, but once they have started, their compliance is no worse than the compliance of patients from other risk groups, which has important implications for clinical trials, medical care, and public health.
AIDS CareZidovudine adherence among individuals with HIV infection
119 Citations1995Richard D. Muma, Michael W. Ross +2 more
Investigating the relationships among health beliefs, attitudes, and zidovudine compliance in individuals with HIV infection suggests that non-compliance is related to attitudes and beliefs about zidvudine, consistent with the HBM, which holds that the balance between barriers and benefits of a health-related behaviour are significant determinants of outcome.
Archives of Internal MedicineA cohort study of drug users' compliance with zidovudine treatment
65 Citations1994B. Broers
AIDSReductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments
63 Citations1997Schlomo Staszewski, Andrew Hill +6 more
ZDV/3TC combination treatment delays the progression of CDC B/C disease compared with control treatments and is seen in subgroups of naive and pre-treated patients, those with high and low CD4 counts and symptomatic and asymptomatic patients.
JAMAPatient compliance and drug failure in protease inhibitor monotherapy
62 Citations1996G. F. Vanhove
AIDS Education and PreventionCompliance with AZT Treatment Regimen of HIV-Seropositive Injection Drug Users: A Neglected Issue
60 Citations1996Robert C. Freeman, Gloria M. Rodriguez +1 more
Although treatment with zidovudine is now recommended for asymptomatic and symptomatic HIV-infected persons with CD4+ cell counts of 0.20 to 0.50 x 10(9)/L and under, data gathered from a small convenience sample of current and former injection drug users with AIDS in the New York City metropolitan region suggest that noncompliance with HIV/AIDS-related therapeutic regimen may be common.
Antiviral TherapyImproved Survival and Reduced Clinical Progression in HIV-Infected Patients with Advanced Disease Treated with Saquinavir plus Zalcitabine
24 Citations1998Richard Haubrich, Jacob Lalezari +63 more
The addition of saquinavir to zal citabine resulted in a significant reduction in progression to AIDS or death compared with zalcitabine alone, and combination treatment with saquinvir plus zal Citabine reduced the risk of progression toAIDS by 49% and death by 68%.
Antimicrobial Agents and ChemotherapyElectronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women
16 Citations1996Sandra M. Geletko, M Segarra +5 more
The data suggest that documentation of medication compliance is essential in studies of chronic prophylaxis in human immunodeficiency virus-infected patients to properly evaluate drug efficacy and to avoid erroneous conclusions concerning drug failure.